Terry Horgan, the patient who was undergoing gene editing treatment being conducted by Cure Rare Disease, a Connecticut-based nonprofit founded by his brother, Rich, to try and save him from the fatal condition, died during the landmark Crispr study.
The only participant in a new study employing a gene-editing technique has passed away, and the trial's organisers are now attempting to determine what caused his death.
Terry Horgan, a 27-year-old who had Duchenne muscular dystrophy, die...
